BACKGROUND: Little is known about the possible role that smoking crack cocaine has on the incidence of HIV infection. Given the increasing use of crack cocaine, we sought to examine whether use of this illicit drug has become a risk factor for HIV infection. METHODS: We included data from people participating in the Vancouver Injection Drug Users Study who reported injecting illicit drugs at least once in the month before enrolment, lived in the greater Vancouver area, were HIV-negative at enrolment and completed at least 1 follow-up study visit. To determine whether the risk of HIV seroconversion among daily smokers of crack cocaine changed over time, we used Cox proportional hazards regression and divided the study into 3 periods: May 1, 1996-Nov. 30, 1999 (period 1), Dec. 1, 1999-Nov. 30, 2002 (period 2), and Dec. 1, 2002-Dec. 30, 2005 (period 3). RESULTS: Overall, 1048 eligible injection drug users were included in our study. Of these, 137 acquired HIV infection during follow-up. The mean proportion of participants who reported daily smoking of crack cocaine increased from 11.6% in period 1 to 39.7% in period 3. After adjusting for potential confounders, we found that the risk of HIV seroconversion among participants who were daily smokers of crack cocaine increased over time (period 1: hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.57-1.85; period 2: HR 1.68, 95% CI 1.01-2.80; and period 3: HR 2.74, 95% CI 1.06-7.11). INTERPRETATION: Smoking of crack cocaine was found to be an independent risk factor for HIV seroconversion among people who were injection drug users. This finding points to the urgent need for evidence-based public health initiatives targeted at people who smoke crack cocaine.
BACKGROUND: Little is known about the possible role that smoking crack cocaine has on the incidence of HIV infection. Given the increasing use of crack cocaine, we sought to examine whether use of this illicit drug has become a risk factor for HIV infection. METHODS: We included data from people participating in the Vancouver Injection Drug Users Study who reported injecting illicit drugs at least once in the month before enrolment, lived in the greater Vancouver area, were HIV-negative at enrolment and completed at least 1 follow-up study visit. To determine whether the risk of HIV seroconversion among daily smokers of crack cocaine changed over time, we used Cox proportional hazards regression and divided the study into 3 periods: May 1, 1996-Nov. 30, 1999 (period 1), Dec. 1, 1999-Nov. 30, 2002 (period 2), and Dec. 1, 2002-Dec. 30, 2005 (period 3). RESULTS: Overall, 1048 eligible injection drug users were included in our study. Of these, 137 acquired HIV infection during follow-up. The mean proportion of participants who reported daily smoking of crack cocaine increased from 11.6% in period 1 to 39.7% in period 3. After adjusting for potential confounders, we found that the risk of HIV seroconversion among participants who were daily smokers of crack cocaine increased over time (period 1: hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.57-1.85; period 2: HR 1.68, 95% CI 1.01-2.80; and period 3: HR 2.74, 95% CI 1.06-7.11). INTERPRETATION: Smoking of crack cocaine was found to be an independent risk factor for HIV seroconversion among people who were injection drug users. This finding points to the urgent need for evidence-based public health initiatives targeted at people who smoke crack cocaine.
Authors: Nadia Fairbairn; Thomas Kerr; Jane A Buxton; Kathy Li; Julio S Montaner; Evan Wood Journal: Drug Alcohol Depend Date: 2006-12-01 Impact factor: 4.492
Authors: Courtney L C Collins; Thomas Kerr; Laura M Kuyper; Kathy Li; Mark W Tyndall; David C Marsh; Julio S Montaner; Evan Wood Journal: J Urban Health Date: 2005-05-04 Impact factor: 3.671
Authors: E E Schoenbaum; D Hartel; P A Selwyn; R S Klein; K Davenny; M Rogers; C Feiner; G Friedland Journal: N Engl J Med Date: 1989-09-28 Impact factor: 91.245
Authors: Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner Journal: BMJ Date: 2009-04-30
Authors: Kora DeBeck; Thomas Kerr; Calvin Lai; Jane Buxton; Julio Montaner; Evan Wood Journal: Am J Drug Alcohol Abuse Date: 2011-08-11 Impact factor: 3.829
Authors: Sasha Uhlmann; M-J Milloy; Thomas Kerr; Ruth Zhang; Silvia Guillemi; David Marsh; Robert S Hogg; Julio S G Montaner; Evan Wood Journal: Addiction Date: 2010-03-10 Impact factor: 6.526
Authors: B Jacka; B C Bray; T L Applegate; B D L Marshall; V D Lima; K Hayashi; K DeBeck; J Raghwani; P R Harrigan; M Krajden; J S G Montaner; J Grebely Journal: J Viral Hepat Date: 2017-09-04 Impact factor: 3.728
Authors: Denise Crooks; Judith Tsui; Bradley Anderson; Shernaz Dossabhoy; Debra Herman; Jane M Liebschutz; Michael D Stein Journal: AIDS Behav Date: 2015-03
Authors: M Eugenia Socías; Kate Shannon; Julio S Montaner; Silvia Guillemi; Sabina Dobrer; Paul Nguyen; Shira Goldenberg; Kathleen Deering Journal: Can J Gastroenterol Hepatol Date: 2015-10-22